History of Natco Pharma Ltd.
NATCO PHARMA LTD. was incorporated on 19th September, 1981 in Andhra Pradesh as a Pvt. limited Comp. as NATCO FINE PHARMACEUTICALS P. LTD. & became a deemed Public Company with effect from 1st July, 1992 under Section 43A of the Act. Subsequently, it changed its name to NATCO PHARMA LTD. on 18th February, 1993 & received change of name certificate.
The Comp. began operations in 1984 with an objective to manufacture conventional & Timed Release Dosage forms of life savings drugs. The company factory is located 35km. away from Hyderabad on Bangalore Highway No. 7. to manufacture a wide range of tablets, capsules, liquids & dry powders using automated equipments
Indigenisation of Microdialysis Cell technology for various dosage forms was taken up as a challenge & Comp. had introduced Antihistaminic, Antianxiety, Antiasthmatic, Cardiac Drugs into Indian Market for first time in sustained action dosage forms. The major products manufactured by Comp. are as follows:
FLOCY [CIPROFLOXACIN HCIs], NATCOCILLIN [AMPICILLINs], NATAMOX [AMOXYCILLINs], TR PHYLLIN [THEOPHYLLINEs], BETACAP TR [PROPRANOLOL HCIs], CARDICAP TR [ISOSORBIDE-Dl-NlTRATEs], IBUBID TR [IBUPROFENs], NACLO TR [DICLOFENAC SODIUMs], CAMRELEASE TR [DIAZEPAMs], CEPIAM TR [CHLORPHENIRAMINE MALEATEs], POTRELEASE TR [POTASSIUM CHLORIDEs], COLDACT [PHENYL PROPANOLAMINEs] HCI + CHLORPHENlRAMINE MALEATEs]
The Comp. holds the necessary licences issued by Drug Control Authorities for manufacture of these drugs at its existing plant at Kothur, Mahaboobnagar. The turnover of the unit increased progressively; the turnover which was at Rs. 730 lacs for year 1989-90 has grown to Rs. 3689.24 Lacs for year 1993-94.
The Comp. has pioneered Timed Release Technology in India by introducing Multi-unit, Multi-layered System for the first time in India in the year 1985. The company's formulation Rubinat is ranked second in the Anticancer Drug Segment & first in the Anthracyclines Segment on the basis of turnover of 1993-94. The Comp. has been awarded Import Substitution Award [1986s] for Timed Release Technology. It has well equipped Research & Development facilities manned by qualified Scientists. Its formulations are exported to the CIS States, Vietnam, Hongkong, China, Netherlands, Nigeria, Tanzania & Kenya. The Annual average exports sales for last three years is 21% of turnover. The Export turnover details for last 3 years are as follows:
[Rs. in lakhss] ----------------------------------------------------- Year Total Export % to Total Turnover Turnover ----------------------------------------------------- 1991-92 1169.36 47.39 4% 1992-93 2840.00 739.86 26% 1993-94 3542.74 1168.64 33% Sept. '94 3402.59 1740.15 51% [6 monthss] -----------------------------------------------------
The Comp. is a recipient of WHO Certificate for maintaining good manutacturing practices. The Comp. is one of contract manufacturers in the pharmaceuticals industry in India & manufactures products for companies including Ranbaxy Laboratories Ltd., Eskayef Ltd., Parke Davis [Is] Ltd., Fulford India Limited, Cadila Ltd., John Wyeth India Ltd., ICI limited & SOL Pharmaceuticals Ltd.
1996
-Natco Pharma [NPLs] was promoted by V C Nannapaneni an NRI based in the US for 13 years.
-Launches the anti-migraine Sumatriptan Succinate under the brand name Suminat.
-Awarded an export house status by Directorate General of Foreign trade Ministry of Commerce
1997
-Natco Pharma Limited have entered into an agreement giving the former business rights for Natco products in Russia & other CIS countries.
-Natco Pharma [NPLs] has achieved the status of 'the complete pharma company' on the merger of its four group companies - Natco Pharma Natco Laboratories Natco Parenterals & Dr.Karanth Pharma Chemical Labs - effective 1 Apr.'95.
-Natco Pharma [NPLs] was promoted in 1983 by V C Nannapaneni an NRI who had worked in the US for 13 years.
1998
-Natco Pharma Ltd has tied up with the US pharmaceutical giant Mallin Krodt for exporting in high volume production of naproxen.
2000
-The Executive Director Dr. K.V. Ranga Rao has resigned but continues in the capacity of director.
2001
-Entered into the formulations segment by recently introducing 34 products in the state.
-The Comp. allotted 42,70 ,500 No. of equity shares at Rs. 17 each on preferential basis.
2002
-Natco Pharma has been given a revamping package from IDBI
-Dr. Mohana R Velagapudi, Dr. K V Ranga Rao & Dr. N Ramakrishna Rao have resigned from the Board w.e.f. March 31, 2002.
-Board Approves the preferential offer of Rs 6.6 crore equity warrants to its promoters group & Rs 6 crore 12 per cent cumulative redeemable preference shares to FIs & banks.
-Natco Pharma Ltd, has received the approval from Therapeutic Goods Administration [TGAs], Australia for its manufacturing facility at Mekaguda in Mehabobnagar.
-Board inducted in to the Audit Committee Dr. K U Mada as a member. The Board constituted the Remuneration Committee with the following members: 1s] Dr. K U Mada, 2s] Mr. Jahar Bhowmik, 3s] Mr. R Monani, 4s] M. G S Murthy.
2003
-Launches the anti-cancer wonder drug under the brand name VEENAT [Imatinib 100mg capsuless]
-A city pharma Comp. has filed a criminal complaint about `theft' of some of its technologies by a senior executive responsible for technology management of its products
- launched Zoldonat Zoledronic Acid for injection. With this launch, NATCO has become the second Comp. to launch Zoledronic Acid in the world, after Novartis, the patent holders.
-Launches Letronat 2.5 mg tablets [Latrozole tabletss]. Letrozole, the non-sterioidal aromatase inhibitor is indicated for first-line treatment of advanced breast cancer in postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.
-Received an order Rs 35-fr for export of citalopram hydrobromide [which is used for treatment as an anti-depressants] for regulated markets & imatinibmesylate [used for treatmemt of chronic myeloid leukaemias]
-Following shareholders have sold shares in the company: 1s] VC Nannapaneni - 90,000 shares, 2s] Time Cap Pharma Labs Pvt. limited - 2,80,000 shares.
-Received a letter from Mr. V. C. Nannapaneni, one of share holders informing the Comp. that he has sold 3,32,554 shares & that his post sale holding is 49,65,346 shares [28.57% of paid up capitals].
- An award has being presented titled as 'DSIR National Award for R&D efforts in the Industry [2003s]' under the Dept. of Scientific & Industrial Research, Ministry of Science & Technology, Govt. of India.
- Mr Rajeev Nannapaneni has been appointed as new Chief Operating Officer of Comp. w.e.f December 1, 2003.
-Promoters offload shares to raise funds
-Unveils new drug for brain tumour therapy, Temozolomide under the brand name `Temonat' indicated for treatment of certain forms of brain tumours.
-Launches Geftinib 250 mg., an anti-cancer drug, under the brand name 'GEFTINAT'
2004
-Natco Pharma Limited has informed that the sad & sudden demise of Mr. Raj Monani, one of Company Board of Directors
-Natco Pharma Ltd has informed the that the Comp. has launched Ganciclovir in 250 mg. capsules & 500 ml injection forms
-Natco Launches anti Cancer Drug, establishes Oncology division
-Natco Pharma Ltd, the Hyderabad-based pharmaceutical Comp. known for its timed-release technology & affordable drugs in cancer therapy, has bagged the award from the Indian Red Cross Society of Chennai
-NATCO launches drug to treat prostate cancer
-NATCO launches drug for Ovarian Cancer
-Launches Curcumin 500 mg capsules under the brand name Turcumin
2005
- Receives Certification of Suitability of Monographs of European Pharmacopoeia for its active pharmaceutical ingredients - Ondansetron Hydrochloride Dihydrate & Sumatriptan Succinate by European Directorate for Quantity of Medicines [EDQMs].
-Natco Pharma Limited signs memorandum of understanding [MoUs] for sharing technology related to manufacture of oncology products.
-Natco Pharma launches anti-migraine drug
-Natco Pharma ties up with Temple University, USA
-Natco Pharma launches Vorizol
2006
-Natco announces launch of Pemnat [Pemetrexeds] for treatment of non-small cell lung cancer
2007
-Natco Pharma Ltd has announced the launch of world class oral contraceptive under the brand name Tarana.
